New KRAS G12D Drug Shrinks Tumors and Slows Cancer Growth
Beyond the “Undruggable”: How KRAS G12D Inhibitors are Redefining the Fight Against Pancreatic Cancer For over three decades, the oncology community viewed the KRAS protein as an untouchable fortress. Considered “undruggable” due to its smooth surface and lack of deep binding pockets, KRAS mutations—particularly the G12D variant—have long been the primary engine driving the most … Read more